FOXO Technologies Announces Issue Notification From USPTO For A Patent Leveraging Machine Learning Approaches To Enable The Commercialization Of Epigenetic Biomarkers
Portfolio Pulse from Benzinga Newsdesk
FOXO Technologies Inc. (NYSE:FOXO) has received an Issue Notification from the United States Patent & Trademark Office (USPTO) for a patent that uses machine learning to enable the commercialization of epigenetic biomarkers. This builds on previous Notices of Allowance issued by the USPTO for two related patents. The patents support the use of machine learning in estimating health aspects and filling in missing or unreliable epigenetic values. The company has generated epigenetic data for over 13,000 individuals to support these patents.
October 13, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
FOXO Technologies has received a patent for a machine learning model that enables the commercialization of epigenetic biomarkers. This could potentially boost the company's position in the biotech industry and open up new commercial markets.
The granting of this patent strengthens FOXO's position in the biotech industry, particularly in the field of epigenetic biomarker technology. This could potentially open up new commercial markets for the company and drive product development, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100